Mesenchymal  ||| S:0 E:12 ||| JJ
stem  ||| S:12 E:17 ||| NN
cells  ||| S:17 E:23 ||| NNS
for  ||| S:23 E:27 ||| IN
acute  ||| S:27 E:33 ||| JJ
lung  ||| S:33 E:38 ||| NN
injury ||| S:38 E:44 ||| NN
:  ||| S:44 E:46 ||| :
preclinical  ||| S:46 E:58 ||| JJ
evidence  ||| S:58 E:67 ||| NN
Several  ||| S:67 E:75 ||| JJ
experimental  ||| S:75 E:88 ||| JJ
studies  ||| S:88 E:96 ||| NNS
have  ||| S:96 E:101 ||| VBP
suggested  ||| S:101 E:111 ||| VBN
that  ||| S:111 E:116 ||| IN
mesenchymal  ||| S:116 E:128 ||| JJ
stem  ||| S:128 E:133 ||| NN
cells  ||| S:133 E:139 ||| NNS
may  ||| S:139 E:143 ||| MD
have  ||| S:143 E:148 ||| VB
value  ||| S:148 E:154 ||| NN
for  ||| S:154 E:158 ||| IN
the  ||| S:158 E:162 ||| DT
treatment  ||| S:162 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
clinical  ||| S:175 E:184 ||| JJ
disorders ||| S:184 E:193 ||| NNS
,  ||| S:193 E:195 ||| ,
including  ||| S:195 E:205 ||| VBG
myocardial  ||| S:205 E:216 ||| JJ
infarction ||| S:216 E:226 ||| NN
,  ||| S:226 E:228 ||| ,
diabetes ||| S:228 E:236 ||| NN
,  ||| S:236 E:238 ||| ,
acute  ||| S:238 E:244 ||| JJ
renal  ||| S:244 E:250 ||| JJ
failure ||| S:250 E:257 ||| NN
,  ||| S:257 E:259 ||| ,
sepsis ||| S:259 E:265 ||| NN
,  ||| S:265 E:267 ||| ,
and  ||| S:267 E:271 ||| CC
acute  ||| S:271 E:277 ||| JJ
lung  ||| S:277 E:282 ||| NN
injury ||| S:282 E:288 ||| NN
.  ||| S:288 E:290 ||| .
In  ||| S:290 E:293 ||| IN
preclinical  ||| S:293 E:305 ||| JJ
studies ||| S:305 E:312 ||| NNS
,  ||| S:312 E:314 ||| ,
mesenchymal  ||| S:314 E:326 ||| JJ
stem  ||| S:326 E:331 ||| NN
cells  ||| S:331 E:337 ||| NNS
have  ||| S:337 E:342 ||| VBP
been  ||| S:342 E:347 ||| VBN
effective  ||| S:347 E:357 ||| JJ
in  ||| S:357 E:360 ||| IN
reducing  ||| S:360 E:369 ||| VBG
lung  ||| S:369 E:374 ||| NN
injury  ||| S:374 E:381 ||| NN
from  ||| S:381 E:386 ||| IN
endotoxin ||| S:386 E:395 ||| NN
,  ||| S:395 E:397 ||| ,
live  ||| S:397 E:402 ||| JJ
bacteria ||| S:402 E:410 ||| NNS
,  ||| S:410 E:412 ||| ,
bleomycin ||| S:412 E:421 ||| NN
,  ||| S:421 E:423 ||| ,
and  ||| S:423 E:427 ||| CC
hyperoxia ||| S:427 E:436 ||| NN
.  ||| S:436 E:438 ||| .
In  ||| S:438 E:441 ||| IN
some  ||| S:441 E:446 ||| DT
studies ||| S:446 E:453 ||| NNS
,  ||| S:453 E:455 ||| ,
the  ||| S:455 E:459 ||| DT
cultured  ||| S:459 E:468 ||| JJ
medium  ||| S:468 E:475 ||| NN
from  ||| S:475 E:480 ||| IN
mesenchymal  ||| S:480 E:492 ||| JJ
stem  ||| S:492 E:497 ||| NN
cells  ||| S:497 E:503 ||| NNS
has  ||| S:503 E:507 ||| VBZ
been  ||| S:507 E:512 ||| VBN
as  ||| S:512 E:515 ||| IN
effective  ||| S:515 E:525 ||| JJ
as  ||| S:525 E:528 ||| IN
the  ||| S:528 E:532 ||| DT
mesenchymal  ||| S:532 E:544 ||| JJ
stem  ||| S:544 E:549 ||| NN
cells  ||| S:549 E:555 ||| NNS
themselves ||| S:555 E:565 ||| PRP
.  ||| S:565 E:567 ||| .
Several  ||| S:567 E:575 ||| JJ
paracrine  ||| S:575 E:585 ||| JJ
mediators  ||| S:585 E:595 ||| NNS
that  ||| S:595 E:600 ||| WDT
can  ||| S:600 E:604 ||| MD
mediate  ||| S:604 E:612 ||| VB
the  ||| S:612 E:616 ||| DT
effect  ||| S:616 E:623 ||| NN
of  ||| S:623 E:626 ||| IN
mesenchymal  ||| S:626 E:638 ||| JJ
stem  ||| S:638 E:643 ||| NN
cells  ||| S:643 E:649 ||| NNS
have  ||| S:649 E:654 ||| VBP
been  ||| S:654 E:659 ||| VBN
identified ||| S:659 E:669 ||| VBN
,  ||| S:669 E:671 ||| ,
including  ||| S:671 E:681 ||| VBG
interleukin-10 ||| S:681 E:695 ||| NNP
,  ||| S:695 E:697 ||| ,
interleukin-1ra ||| S:697 E:712 ||| NNP
,  ||| S:712 E:714 ||| ,
keratinocyte  ||| S:714 E:727 ||| JJ
growth  ||| S:727 E:734 ||| NN
factor ||| S:734 E:740 ||| NN
,  ||| S:740 E:742 ||| ,
and  ||| S:742 E:746 ||| CC
prostaglandin  ||| S:746 E:760 ||| JJ
E2 ||| S:760 E:762 ||| NN
.  ||| S:762 E:764 ||| .
Further  ||| S:764 E:772 ||| RBR
preclinical  ||| S:772 E:784 ||| JJ
studies  ||| S:784 E:792 ||| NNS
are  ||| S:792 E:796 ||| VBP
needed ||| S:796 E:802 ||| VBN
,  ||| S:802 E:804 ||| ,
as  ||| S:804 E:807 ||| RB
is  ||| S:807 E:810 ||| VBZ
planning  ||| S:810 E:819 ||| VBG
for  ||| S:819 E:823 ||| IN
clinical  ||| S:823 E:832 ||| JJ
trials  ||| S:832 E:839 ||| NNS
for  ||| S:839 E:843 ||| IN
acute  ||| S:843 E:849 ||| JJ
lung  ||| S:849 E:854 ||| NN
injury ||| S:854 E:860 ||| NN
.  ||| S:860 E:862 ||| .
